These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 29793444)
1. PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol. Richardson M; Sidhom M; Gallagher S; Grand M; Pryor D; Bucci J; Wilton L; Arumugam S; Keats S; Martin JM BMC Cancer; 2018 May; 18(1):588. PubMed ID: 29793444 [TBL] [Abstract][Full Text] [Related]
2. Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial. Wegener E; Sidhom M; Pryor D; Bucci J; Yeoh K; Richardson M; Greer P; Wilton L; Gallagher S; Schmidt L; Arumugam S; Keats S; Brown S; Glyde A; Martin JM Eur Urol Oncol; 2024 Oct; 7(5):1042-1050. PubMed ID: 38302321 [TBL] [Abstract][Full Text] [Related]
3. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer. Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713 [TBL] [Abstract][Full Text] [Related]
4. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Alongi F; Fogliata A; Navarria P; Tozzi A; Mancosu P; Lobefalo F; Reggiori G; Clivio A; Cozzi L; Scorsetti M Strahlenther Onkol; 2012 Nov; 188(11):990-6. PubMed ID: 23053143 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292 [TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. Eckert F; Alloussi S; Paulsen F; Bamberg M; Zips D; Spillner P; Gani C; Kramer U; Thorwarth D; Schilling D; Müller AC BMC Cancer; 2013 Jan; 13():27. PubMed ID: 23336502 [TBL] [Abstract][Full Text] [Related]
10. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients. Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial. Kim YJ; Ahn H; Kim CS; Lee JL; Kim YS Trials; 2018 Apr; 19(1):212. PubMed ID: 29609646 [TBL] [Abstract][Full Text] [Related]
12. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol. Martin J; Keall P; Siva S; Greer P; Christie D; Moore K; Dowling J; Pryor D; Chong P; McLeod N; Raman A; Lynam J; Smart J; Oldmeadow C; Tang CI; Murphy DG; Millar J; Tai KH; Holloway L; Reeves P; Hayden A; Lim T; Holt T; Sidhom M BMJ Open; 2019 Aug; 9(8):e030731. PubMed ID: 31434782 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis. Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496 [TBL] [Abstract][Full Text] [Related]
14. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241 [TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N; Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791 [TBL] [Abstract][Full Text] [Related]
16. A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancer. Den RB; Greenspan J; Doyle LA; Harrison AS; Peng C; Williams NL; Lallas CD; Trabulsi EJ; Gomella LG; Hurwitz MD; Leiby B; Dicker AP Brachytherapy; 2020; 19(3):282-289. PubMed ID: 32217038 [TBL] [Abstract][Full Text] [Related]
17. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864 [TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129 [TBL] [Abstract][Full Text] [Related]
19. [Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy]. Quintin K; Créhange G; Graff P Cancer Radiother; 2024 Aug; 28(4):333-340. PubMed ID: 39155168 [TBL] [Abstract][Full Text] [Related]
20. Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities. Vassis S; Nöldeke B; Christiansen H; von Klot CA; Merten R Strahlenther Onkol; 2020 Jul; 196(7):598-607. PubMed ID: 32040691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]